| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/05/2002 | US20020123488 Pyrazine and triazine derivatives of 1,2,4,5-tetrahydro-Benzo or Thieno [d] azepine |
| 09/05/2002 | US20020123485 For therapy of hypertension, cirrhosis and ascites |
| 09/05/2002 | US20020123484 For therapy of immunologic disorders such as transplant rejection, rheumatoid arthritis. multiple sclerosis, inflammatory bowel disease, lupus, graft vs. host disease |
| 09/05/2002 | US20020123468 Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease |
| 09/05/2002 | US20020123462 Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 09/05/2002 | US20020123143 Cellular composition for use in the treatment and repair of bone and nervous system disorders |
| 09/05/2002 | US20020123141 Recovering embryonic-like stem cells from a placenta; obtain placenta, drain cord blood, flush placenta with anticoagulant solution, recover cells |
| 09/05/2002 | US20020123099 Highly expressible genes |
| 09/05/2002 | US20020123047 dexB |
| 09/05/2002 | US20020123042 Detection of loss of the wild-type hubub1 gene |
| 09/05/2002 | US20020122857 Adding an organic solvent to an aqueous extract of soybeans and purifying precipitate |
| 09/05/2002 | US20020122836 Extract of Arales, Asterales, Coniferales, Equisetales, Euphorbiales, Geraniales, Lamiales, Lillales, Pteridophyta, Ranales, Rhamnales, Rutales, Scrophulariales, Umbellales, or Urticales. |
| 09/05/2002 | US20020122817 Solid instant-release forms of administration and process for producing the same |
| 09/05/2002 | US20020122804 Inhibition of transglutaminase-mediated microbial interaction with a mammalian host |
| 09/05/2002 | US20020122795 Compositions containing gangliosides for use in the treatment of skin disorders |
| 09/05/2002 | DE10110325A1 Phenylderivate 2 Phenyl derivatives 2 |
| 09/05/2002 | DE10109859A1 Neuartige Aminodicarbonsäurederivate Novel Aminodicarbonsäurederivate |
| 09/05/2002 | DE10109280A1 Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen Indole derivatives having an inhibitory effect on protein kinases |
| 09/05/2002 | DE10109155A1 Verwendung von BK-RiV-Präparaten oder ihrer Einzelbestandteile zum Schutze der gesunden Leber, zur Therapie von Lebererkrankungen und zur Leberrekonstruktion nach Leberdestruktion beim Menschen und bei Tieren Use of BK-RiV preparations or its individual components for the Protection of healthy liver, for the treatment of liver diseases and liver reconstruction after liver destruction in humans and in animals |
| 09/05/2002 | DE10108752A1 Neue Substituierte Imidazotriazinone New Substituted imidazotriazinones |
| 09/05/2002 | DE10108470A1 Verfahren zur Herstellung optisch aktiver Dihydropyrone A process for preparing optically active dihydropyrones |
| 09/04/2002 | EP1236736A1 2-aminopurine derivatives |
| 09/04/2002 | EP1236725A1 Novel 1,8-naphthyridin-2(1h)-one derivatives |
| 09/04/2002 | EP1236723A1 Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof |
| 09/04/2002 | EP1236720A1 Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors |
| 09/04/2002 | EP1236712A1 Amidinophenylpyruvic acid derivative |
| 09/04/2002 | EP1236711A2 Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood |
| 09/04/2002 | EP1236476A1 Medicinal compositions for oral use |
| 09/04/2002 | EP1236475A2 Combination therapy for osteoporosis consisting of an estrogen agonist/antagonist and a growth hormone secretagogue |
| 09/04/2002 | EP1236473A2 Self-assembling polynucleotide delivery system |
| 09/04/2002 | EP1236468A1 Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders |
| 09/04/2002 | EP1236465A2 Use of legume products for the treatment of external aggressions |
| 09/04/2002 | EP1236463A1 Topical cosmetic composition |
| 09/04/2002 | EP1235934A2 Screening method for candidate drugs |
| 09/04/2002 | EP1235924A1 Antisense modulation of rank expression |
| 09/04/2002 | EP1235912A2 Tumour-specific vector for gene therapy |
| 09/04/2002 | EP1235907A1 6 human secreted proteins |
| 09/04/2002 | EP1235860A2 G-protein coupled receptors |
| 09/04/2002 | EP1235851A2 Regulators of the hedgehog pathway, compositions and uses related thereto |
| 09/04/2002 | EP1235849A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 09/04/2002 | EP1235846A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 09/04/2002 | EP1235844A1 28 human secreted proteins |
| 09/04/2002 | EP1235843A1 26 human secreted proteins |
| 09/04/2002 | EP1235842A1 Rna interference pathway genes as tools for targeted genetic interference |
| 09/04/2002 | EP1235841A1 Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions |
| 09/04/2002 | EP1235830A2 PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS |
| 09/04/2002 | EP1235827A2 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 09/04/2002 | EP1235825A1 Novel benzoimidazole derivatives useful as antiproliferative agents |
| 09/04/2002 | EP1235815A1 Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| 09/04/2002 | EP1235812A2 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 09/04/2002 | EP1235810A1 Process of making substituted pyrazoles |
| 09/04/2002 | EP1235803A1 Urea compounds having muscarinic receptor antagonist activity |
| 09/04/2002 | EP1235802A1 Carbamate derivatives having muscarinic receptor antagonist activity |
| 09/04/2002 | EP1235801A2 Solid pharmaceutical preparation |
| 09/04/2002 | EP1235798A1 1,4 substituted piperidinyl nmda/nr2b antagonists |
| 09/04/2002 | EP1235793A2 Vla-4 integrin antagonists |
| 09/04/2002 | EP1235787A1 $g(b)2-ADRENERGIC RECEPTOR AGONISTS |
| 09/04/2002 | EP1235776A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| 09/04/2002 | EP1235618A2 Bioconjugation in vivo to pulmonary or blood components |
| 09/04/2002 | EP1235596A2 Use of lytic toxins and toxin conjugates |
| 09/04/2002 | EP1235592A1 COMBINATION OF COMPOUNDS THAT INHIBIT THE BIOLOGICAL EFFECTS OF TNF-$g(a) AND CD95L IN A MEDICAMENT |
| 09/04/2002 | EP1235586A1 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions |
| 09/04/2002 | EP1235584A2 Virus immunologic determinants |
| 09/04/2002 | EP1235580A2 Transdermal system containing acetylsalicylic acid for treatment of migraine |
| 09/04/2002 | EP1235578A2 Use of hymenialdisine or derivatives thereof in the manufacture of medicaments |
| 09/04/2002 | EP1235577A2 Protease inhibitors |
| 09/04/2002 | EP1235574A2 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| 09/04/2002 | EP1235570A2 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics |
| 09/04/2002 | EP1235569A2 Medicament and combination of compatible medicaments |
| 09/04/2002 | EP1235568A2 Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells |
| 09/04/2002 | EP1235565A1 Use of 5ht 3 agonists for relaxing the fundus |
| 09/04/2002 | EP1054886B1 Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors |
| 09/04/2002 | EP1049478B1 Composition containing propargylamine for enhancing cancer therapy |
| 09/04/2002 | EP1037888B1 (e)-3-[1-n-butyl- 5-[2-(2-carboxyphenyl)methoxy- 4-chlorophenyl]-1h- pyrazol-4-yl]-2- [(5- methoxy-2,3- dihydrobenzofuran-6-yl)methyl]- prop-2-enoic acid monoargininyl salt |
| 09/04/2002 | EP1037646B1 Ginkgo biloba leaf extracts with a reduced 4'-o-methylpyridoxine and biflavone content |
| 09/04/2002 | EP1009425B1 Use of Latency Associated Peptide for the manufacture of a medicament for increasing wound healing. |
| 09/04/2002 | EP0999849B1 Use of lbp in the treatment of septicaemia |
| 09/04/2002 | EP0991647B1 Eprosartan monohydrate |
| 09/04/2002 | EP0969828B1 Butyrate prodrugs derived from lactic acid |
| 09/04/2002 | EP0966476B1 Quinazolinone compounds |
| 09/04/2002 | EP0944629B1 Biaryl-pyridoquinazolinone derivatives as anti-cancer agents |
| 09/04/2002 | EP0915864B1 Gastroprotective flavone/flavanone compounds with therapeutic effect on inflammatory bowel disease |
| 09/04/2002 | EP0906309B1 Modified form of the r(-)-n-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride |
| 09/04/2002 | EP0889878B1 Bisarylcyclobutene derivates as cyclooxygenase inhibitors |
| 09/04/2002 | EP0858459B1 Novel acid pyrazole derivatives, preparation method therefor, use thereof as drugs, novel use therefor, and pharmaceutical compositions containing such derivatives |
| 09/04/2002 | EP0830348B1 Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
| 09/04/2002 | EP0809636B1 Substituted isoxazoles for the treatment of inflammation |
| 09/04/2002 | EP0801574A4 Modulation of integrin-mediated signal transduction |
| 09/04/2002 | EP0771209B1 Novel peptides |
| 09/04/2002 | EP0764208B1 Bmp-9 compositions |
| 09/04/2002 | EP0746551B1 Optically pure 4-aryl-2-hydroxytetronic acids |
| 09/04/2002 | EP0738107B1 Inhibitors of fatty acid synthesis as antimicrobial agents |
| 09/04/2002 | EP0205475B2 Recombinant methods for production of serine protease inhibitors and dna sequences useful for same |
| 09/04/2002 | CN1367875A Induction method of TH1-like response in vitro |
| 09/04/2002 | CN1367828A Oligonucleotides for inhibiting expression of human eg5 |
| 09/04/2002 | CN1367793A Neuromedin B and somatostatin receptor agonists |
| 09/04/2002 | CN1367783A Antipsychotic cyclic N-aralkyl amines |
| 09/04/2002 | CN1367778A Novel carboxylic acid derivatives with 5,6 substitutedpyrimidine ring, their production and utilization thereof as endothelin receptor antagonists |
| 09/04/2002 | CN1367777A Benzenamine derivatives as anti-coagulants |
| 09/04/2002 | CN1367701A Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |